logo
  • SELECT LICENSE :

  • US $4,299.00
  • US $8,599.00

Immortalized Cell Line Market, by method (HTERT Expression, Virus Induction, Inactivation of Tumor Suppression Genes, Others)), By Application (diagnostics, Vaccine Production, Drug Discovery, Tissue Engineering and Regenerative Medicine, Others) opportunities and forecast 2020-2027

  • DLR2166
  • 19 September, 2020
  • Pharma & Healthcare
  • Pages: 120
  • Global
Market Overview

Immortalized cell lines are tumorous cells that do not stop replicating or cells which have been artificially operated to proliferate forever and can, thus, be grown over the several generations. These cell lines are anticipated to grow due to rise in innovative technologies and vaccine production.

Besides, ability of cell line culture to offer more physiologically pertinent information and more precise data in-vitro examinations has led the these cell line culture systems to become the acceptable in contrast to media culture.

The growing application in pharmaceutical and biotech companies and hospitals, growing number of patients in the need of organ transplantation, and rise in patient population affected by the cancer are major drivers driving market growth. However, high cost of the equipment and developing stable strain of the cell line and preventing and maintaining it from the contamination may hinder growth of the market.

Segment Overview

The growing demand for the organ donation due to shortage in availability of organs is driving need for artificially produced biological cells. According to the U.S. Department of the Health and Human Services Organ Procurement and the Transplantation Network (OPTN), as of Nov 2016, almost 121,678 patients were waiting for life-saving organ transplant.

This growing demand for organ transplant is predictable to drive growth of the market during forecast period. Moreover, increasing application in the biotech and pharmaceutical companies and the hospitals and increase in patient population affected by the cancer are expected to support the market growth. On other hand, high cost of equipment and the developing stable strain of cell line coupled with the maintaining and preventing it from the contamination is expected to hamper market growth.

Regional Overview

The North America is projected to dominate global immortalized cell line market over the forecast period. This is accredited to increase in occurrence of cancer, presence of well-established biotechnology and pharmaceutical industry, growing awareness of the immortalized cell lines, and the strong research funding.
The European market for the immortalized cell line is predictable to be second-largest during forecast period. Growing government support, rising cases of the cancer and well-developed technology are anticipated to boost growth of market in this region.

Asia-Pacific is projected to be fastest-growing market owing to the growing expenditure on the healthcare by government and the private sector companies. Furthermore, the rising awareness about healthcare and the large untapped patient population have also led to increased focus of the key players on the expansion in the region.

Competitor overview

In April 2018, Company Lonza Group, AG declared the opening of worlds largest devoted cell-and-gene-therapy plant facility in the Pearland, Greater Houston, (U.S.). The site was built in expectation of rising demand from the developers of cell and the gene therapies.

In August 2017, company named, Thermo Fisher Scientific acquired the Patheon for USD 7.2 million. Patheon’s CDMO amenities are likely to accompany Thermo Fisher Scientific’s technologies designed to upkeep with the clinical trials, research, and production.

Key Players
  1. Thermo Fisher Scientific
  2. ATCC (American Type Culture Collection Inc.)
  3. Valneva
  4. Sartorius AG
  5. Lonza Group, AG
  6. Merck KGaA
  7. Selexis SA
  8. WuXi App Tec
  9. European Collection of Authenticated Cell Cultures (ECACC)
  10. Corning Incorporated

Market Segmentation

By Type
  • Virus Induction
  • Inactivation of Tumor Suppression Genes
  • HTERT Expression
  • Others
By Application
  • Diagnostics
  • Drug Discovery
  • Tissue Engineering & Regenerative Medicine
  • Vaccine Production
  • Others
By Geography
  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • UAE
    • Rest of LAMEA


1 Report Prologue 13

    2 Executive Summary 15

      3 Market Introduction 18

      • 3.1 Scope of Study 19
      • 3.2 Research Objective 19
      • 3.3 List of Assumptions 19
      • 3.4 Market Structure 20

      4 Research Methodology 21

      • 4.1 Research Process 22
      • 4.2 Primary Research 23
      • 4.3 Secondary Research 24
      • 4.4 Market Size Estimation 25
      • 4.5 Forecast Model 25

      5 Market Dynamics 26

      • 5.1 Introduction 27
      • 5.2 Drivers 28
        • 5.2.1 Increasing application in biotech & pharmaceutical companies and hospitals 28
        • 5.2.2 Growing number of patients in need of organ transplantation 28
        • 5.2.3 Rise in the patient population affected by cancer 29
      • 5.3 Restraints 29
        • 5.3.1 High cost of equipment 29
        • 5.3.2 Developing stable and authentic cell lines 29
      • 5.4 Opportunities 30
        • 5.4.1 Entering untapped markets 30
        • 5.4.2 Increasing use of cell line culture in cancer and stem cell research 30

      6 Market Factor Analysis 31

      • 6.1 Porters Five Forces Analysis 32
        • 6.1.1 Bargaining Power of Suppliers 32
        • 6.1.2 Bargaining Power of Buyers 32
        • 6.1.3 Threat of New Entrants 32
        • 6.1.4 Threat of Substitutes 33
        • 6.1.5 Intensity of Rivalry 33
      • 6.2 Supply chain analysis 33
        • 6.2.1 R&D 33
        • 6.2.2 Manufacturing 33
        • 6.2.3 Distribution & Sales 34
        • 6.2.4 Post-Sales Monitoring 34
      • 6.3 Investment Opportunities 34
      • 6.4 Pricing Analysis 34

      7 Global Immortalized Cell Line Market, by Method 35

      • 7.1 Overview 36
        • 7.1.1 Virus Induction 38
        • 7.1.2 HTERT Expression 39
        • 7.1.3 Inactivation of Tumour Suppression Genes 40
        • 7.1.4 Others 40

      8 Global Immortalized Cell Line Market, by Application 41

      • 8.1 Overview 42
        • 8.1.1 Diagnostics 43
        • 8.1.2 Drug Discovery 43
        • 8.1.3 Vaccine Production 44
        • 8.1.4 Tissue Engineering and Regenerative Medicines 45
        • 8.1.5 Others 45

      9 Global Immortalized Cell Line Market, by End-user 46

      • 9.1 Overview 47
        • 9.1.1 Introduction 47
        • 9.1.2 Pharmaceutical and Biopharmaceutical Companies 48
        • 9.1.3 Contract Research Organizations 48
        • 9.1.4 Research Laboratories 49

      10 Global Immortalized Cell Line Market, By Region 50

      • 10.1 Overview 51
      • 10.2 Americas 52
        • 10.2.1 North America 54
          • 10.2.1.1 US 57
          • 10.2.1.2 Canada 58
        • 10.2.2 South America 60
      • 10.3 Europe 62
        • 10.3.1 Western Europe 65
          • 10.3.1.1 Germany 67
          • 10.3.1.2 France 69
          • 10.3.1.3 U.K. 71
          • 10.3.1.4 Italy 73
          • 10.3.1.5 Spain 75
          • 10.3.1.6 Rest of Western Europe 76
        • 10.3.2 Eastern Europe 78
      • 10.4 Asia Pacific 80
        • 10.4.1 Japan 82
        • 10.4.2 China 84
        • 10.4.3 India 86
        • 10.4.4 South Korea 87
        • 10.4.5 Rest of Asia Pacific 89
      • 10.5 The Middle East and Africa 91
        • 10.5.1 Middle East 93
        • 10.5.2 Africa 95

      11 Competitive Landscape 97

      • 11.1 Company Market Share Analysis 98
        • 11.1.1 Introduction 98
      • 11.2 Competitive Landscape 99
        • 11.2.1 Introduction 99
      • 11.3 Key Developments 100

      12 Company Profiles 101

      • 12.1 Thermo Fisher Scientific 102
        • 12.1.1 Company Overview 102
        • 12.1.2 Financial Overview 102
        • 12.1.3 Products Offering 103
        • 12.1.4 Key Developments 103
        • 12.1.5 SWOT Analysis 103
        • 12.1.6 Key Strategy 104
      • 12.2 ATCC (American Type Culture Collection Inc.) 105
        • 12.2.1 Company Overview 105
        • 12.2.2 Financial Overview 105
        • 12.2.3 Products Offering 105
        • 12.2.4 Key Developments 106
        • 12.2.5 SWOT Analysis 107
        • 12.2.6 Key Strategy 107
      • 12.3 Valneva 108
        • 12.3.1 Company Overview 108
        • 12.3.2 Financial Overview 108
        • 12.3.3 Products Offering 108
        • 12.3.4 1.3.4 Key Developments 109
        • 12.3.5 SWOT Analysis 109
        • 12.3.6 Key Strategy 109
      • 12.4 Sartorius AG 110
        • 12.4.1 Company Overview 110
        • 12.4.2 Financial Overview 110
        • 12.4.3 Products Offering 111
        • 12.4.4 Key Developments 111
        • 12.4.5 SWOT Analysis 111
        • 12.4.6 Key Strategy 111
      • 12.5 Lonza Group, AG 112
        • 12.5.1 Company Overview 112
        • 12.5.2 Financial Overview 112
        • 12.5.3 Products Offering 112
        • 12.5.4 Key Developments 113
        • 12.5.5 Swot Analysis 113
        • 12.5.6 Key Strategy 113
      • 12.6 Merck KGaA 114
        • 12.6.1 Company Overview 114
        • 12.6.2 Financial Overview 114
        • 12.6.3 Products Offering 115
        • 12.6.4 Key Developments 115
        • 12.6.5 SWOT Analysis 115
        • 12.6.6 Key Strategy 115
      • 12.7 Selexis SA 116
        • 12.7.1 Company Overview 116
        • 12.7.2 Financial Overview 116
        • 12.7.3 Products Offering 116
        • 12.7.4 Key Developments 116
        • 12.7.5 SWOT Analysis 117
        • 12.7.6 Key Strategy 117
      • 12.8 Wuxi App Tec 118
        • 12.8.1 Company Overview 118
        • 12.8.2 Financial Overview 118
        • 12.8.3 Products Offering 119
        • 12.8.4 Key Developments 119
        • 12.8.5 SWOT Analysis 119
        • 12.8.6 Key Strategy 119
      • 12.9 European Collection of Authenticated Cell Cultures (ECACC) 120
        • 12.9.1 Company Overview 120
        • 12.9.2 Financial Overview 120
        • 12.9.3 Products Offering 120
        • 12.9.4 Key Developments 120
        • 12.9.5 SWOT Analysis 121
        • 12.9.6 Key Strategy 121
      • 12.10 Corning Incorporated 122
        • 12.10.1 Company Overview 122
        • 12.10.2 Financial Overview 122
        • 12.10.3 Products Offering 123
        • 12.10.4 Key Developments 123
        • 12.10.5 SWOT Analysis 123
        • 12.10.6 Key Strategy 123

      13 Appendix 124

      • 13.1 Discussion Blue Print 125

      Report You Might be Interested